Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15719198 | 0.96 | L3MBTL1 (0.39) | BRD4APEX1BLML3MBTL1MEN1 | |
| SCHEMBL15361830 | 0.93 | BRD4 (0.41) | BRD4APEX1BLML3MBTL1MEN1 | |
| SCHEMBL5009833 | 0.91 | L3MBTL1 (0.40) | BRD4APEX1BLML3MBTL1MEN1 | |
| SCHEMBL563597 | 0.90 | L3MBTL1 (0.39) | BRD4APEX1BLML3MBTL1MEN1 | |
| SCHEMBL2336934 | 0.88 | L3MBTL1 (0.40) | BRD4APEX1BLML3MBTL1MEN1 | |
| SCHEMBL25637726 | 0.84 | APEX1 (0.58) | BRD4APEX1BLML3MBTL1MEN1 | |
| SCHEMBL563437 | 0.84 | APEX1 (0.58) | BRD4APEX1BLML3MBTL1MEN1 | |
| SCHEMBL21881953 | 0.82 | BRD4 (0.46) | BRD4L3MBTL1MEN1CYP2C19KMT2A | |
| SCHEMBL27947211 | 0.80 | BRD4 (0.41) | BRD4L3MBTL1MEN1CYP2C19KMT2A | |
| SCHEMBL5012989 | 0.79 | PTGER4 (0.43) | BRD4L3MBTL1MEN1CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358276-B2 | for treating neurological disorders such as epilepsy, neuropathic pain, bipolar disorder or migraine; 2-(2-oxo-4-propyl-1-pyrrolidinyl)butanamide; neuroprotective agent | UCB, S.A. (BE) | 2008-04-15 | — | — | US | disclosed |
| US-20050171188-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171188-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | BRD4 2140/4885APEX1 1453/4885BLM 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.